- United States
- Our innovation
Our innovation
We innovate with purpose to lead where medicine is going.
Our focus areas
Our discovery, product development and supply process
With our cross-functional approach to innovation, deep expertise, and global footprint, we aim to develop therapies for patients by inventing, licensing and acquiring new molecular entities and exploring new pathways and multi-modality treatment approaches.
23-255-richard-tillyer-part-1-who-we-are-1.mp4
23-255-richard-tillyer-part-1-who-we-are-1.mp4
Research & development
We believe there are no limits to what science can do. We work to bring breakthroughs beyond medicine to help transform patients’ lives.
Our pipeline
Our robust pipeline spans multiple focus areas with a number of programs in development, as well as select novel therapy programs recently approved, or with potential filings in the United States/European Union.
Data science and digital health
Data science and digital health accelerate our R&D engine across the entire value-chain – from target discovery and patient segmentation to drug design, CMC process optimization and all facets of clinical development.
Latest news
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
JNJ-2113 long-term extension FRONTIER 2 study demonstrated sustained efficacy from Week 16 to Week 52 and safety results consistent with previously reported data (FRONTIER 1 Study) in a late-breaking oral presentation at the American Academy of Dermatology 2024 Annual Meeting
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Approval is based on results from the Phase 3 PAPILLON study, which demonstrated RYBREVANT® plus chemotherapy reduced the risk of disease progression or death by 61 percent versus chemotherapy alone in patients with previously untreated NSCLC with EGFR exon 20 insertion mutations. National Comprehensive Cancer Network ® (NCCN ®) updated its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) to recommend amivantamab-vmjw (RYBREVANT®) plus chemotherapy as a preferred first-line regimen for patients with NSCLC with EGFR exon 20 insertion mutations.
Johnson & Johnson Announces Expansion of IMBRUVICA® (ibrutinib) Label in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications
IMBRUVICA® is now the only Bruton’s tyrosine kinase inhibitor (BTKi) approved with an oral suspension formulation, providing additional flexibility for patients who may have difficulty swallowing tablets or capsules
Contact us
Our R&D leadership team is made up of passionate individuals who are helping to transform the future of healthcare.